Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania. more
Time Frame | SVRA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.17% | -3.39% | 0.2% |
1-Month Return | 8.78% | -1.92% | 2.72% |
3-Month Return | -27.31% | -10.54% | 7.31% |
6-Month Return | -16.8% | -4.47% | 10.44% |
1-Year Return | -30% | 4.06% | 27.53% |
3-Year Return | 172.88% | 0.94% | 30.88% |
5-Year Return | 105.1% | 36.67% | 89.21% |
10-Year Return | -89.78% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 257.00K | 1.00K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.39,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 1.01M | 35.04K | 367.00K | 167.00K | 44.26M | [{"date":"2019-12-31","value":2.28,"profit":true},{"date":"2020-12-31","value":0.08,"profit":true},{"date":"2021-12-31","value":0.83,"profit":true},{"date":"2022-12-31","value":0.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.01M) | 221.96K | (367.00K) | (167.00K) | (44.26M) | [{"date":"2019-12-31","value":-455.03,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-165.34,"profit":false},{"date":"2022-12-31","value":-75.24,"profit":false},{"date":"2023-12-31","value":-19941.25,"profit":false}] |
Gross Margin | - | 86.37% | (36700.00%) | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-42493.31,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 52.17M | 48.66M | 40.63M | 38.04M | 15.74M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.27,"profit":true},{"date":"2021-12-31","value":77.88,"profit":true},{"date":"2022-12-31","value":72.92,"profit":true},{"date":"2023-12-31","value":30.18,"profit":true}] |
Operating Income | (79.03M) | (49.30M) | (41.48M) | (38.84M) | (60.01M) | [{"date":"2019-12-31","value":-7902500000,"profit":false},{"date":"2020-12-31","value":-4930000000,"profit":false},{"date":"2021-12-31","value":-4147700000,"profit":false},{"date":"2022-12-31","value":-3883900000,"profit":false},{"date":"2023-12-31","value":-6000700000,"profit":false}] |
Total Non-Operating Income/Expense | 782.00K | (1.80M) | (3.82M) | 601.00K | 9.74M | [{"date":"2019-12-31","value":8.02,"profit":true},{"date":"2020-12-31","value":-18.44,"profit":false},{"date":"2021-12-31","value":-39.19,"profit":false},{"date":"2022-12-31","value":6.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (78.17M) | (49.62M) | (43.01M) | (38.15M) | (54.70M) | [{"date":"2019-12-31","value":-7817300000,"profit":false},{"date":"2020-12-31","value":-4961500000,"profit":false},{"date":"2021-12-31","value":-4301400000,"profit":false},{"date":"2022-12-31","value":-3815000000,"profit":false},{"date":"2023-12-31","value":-5469800000,"profit":false}] |
Income Taxes | 26.85M | 1.48M | 2.28M | 796.00K | 797.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":5.52,"profit":true},{"date":"2021-12-31","value":8.5,"profit":true},{"date":"2022-12-31","value":2.96,"profit":true},{"date":"2023-12-31","value":2.97,"profit":true}] |
Income After Taxes | (105.03M) | (51.10M) | (45.30M) | (38.95M) | (55.49M) | [{"date":"2019-12-31","value":-10502500000,"profit":false},{"date":"2020-12-31","value":-5109700000,"profit":false},{"date":"2021-12-31","value":-4529600000,"profit":false},{"date":"2022-12-31","value":-3894600000,"profit":false},{"date":"2023-12-31","value":-5549500000,"profit":false}] |
Income From Continuous Operations | (78.17M) | (49.62M) | (43.01M) | (38.15M) | (54.70M) | [{"date":"2019-12-31","value":-7817300000,"profit":false},{"date":"2020-12-31","value":-4961500000,"profit":false},{"date":"2021-12-31","value":-4301400000,"profit":false},{"date":"2022-12-31","value":-3815000000,"profit":false},{"date":"2023-12-31","value":-5469800000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (105.03M) | (51.10M) | (45.30M) | (38.95M) | (54.70M) | [{"date":"2019-12-31","value":-10502500000,"profit":false},{"date":"2020-12-31","value":-5109700000,"profit":false},{"date":"2021-12-31","value":-4529600000,"profit":false},{"date":"2022-12-31","value":-3894600000,"profit":false},{"date":"2023-12-31","value":-5469800000,"profit":false}] |
EPS (Diluted) | (1.93) | (0.84) | (0.34) | (0.25) | (0.33) | [{"date":"2019-12-31","value":-193,"profit":false},{"date":"2020-12-31","value":-84,"profit":false},{"date":"2021-12-31","value":-34,"profit":false},{"date":"2022-12-31","value":-25,"profit":false},{"date":"2023-12-31","value":-33,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SVRA | |
---|---|
Cash Ratio | 17.16 |
Current Ratio | 17.70 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SVRA | |
---|---|
ROA (LTM) | -26.39% |
ROE (LTM) | -47.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SVRA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SVRA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 131146.00 |
P/B | 2.81 |
Price/FCF | NM |
EV/R | 11.91 |
EV/Ebitda | NM |
PEG | NM |
Savara Inc (SVRA) share price today is $3.09
Yes, Indians can buy shares of Savara Inc (SVRA) on Vested. To buy Savara Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SVRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Savara Inc (SVRA) via the Vested app. You can start investing in Savara Inc (SVRA) with a minimum investment of $1.
You can invest in shares of Savara Inc (SVRA) via Vested in three simple steps:
The 52-week high price of Savara Inc (SVRA) is $5.7. The 52-week low price of Savara Inc (SVRA) is $2.81.
The price-to-earnings (P/E) ratio of Savara Inc (SVRA) is
The price-to-book (P/B) ratio of Savara Inc (SVRA) is 2.81
The dividend yield of Savara Inc (SVRA) is 0.00%
The market capitalization of Savara Inc (SVRA) is $559.48M
The stock symbol (or ticker) of Savara Inc is SVRA